Company Overview: Cytori Therapeutics

About the Company

Cytori Therapeutics
Tweeter Linkedin

Cytori Cell TherapyTM is under evaluation in the United States for treatment of patients with hand and finger involvement due to the autoimmune condition scleroderma, as well as patients with symptomatic knee osteoarthritis. Our technology is approved in many countries around the world, and we have a number of active global partnerships with academic hospitals, companies and government agencies that share our interest in bringing Cytori Cell TherapyTM to patients in need.

Investor Toolkit

Company News

  • Cytori Closes Rights Offering for Gross Proceeds of $10 Million

    SAN DIEGO, Nov. 28, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (“Cytori”) (CYTX) announced today the closing of its rights offering (the “Rights Offering”) to subscribe for units at a subscription price of $1,000 per unit. Pursuant to the Rights...

  • Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS

    Pharmacokinetic Bioequivalence Shown for Cytori’s ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride, Results Presented at the 2017 American Association of Pharmaceutical Scientists Annual Meeting SAN DIEGO, Nov. 16, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced the...

  • Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis

    SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or “the Company”) today announced a new investigator initiated U.S. clinical trial for hip osteonecrosis. Details of the trial can be assessed at Cytori Cell Therapy™ technology is...

  • STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress

    SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or “the Company”) announced today that its U.S. STAR clinical trial assessing the safety and efficacy  of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma (SSc)...

Email Subscription


Follow this blog

Get every new post delivered right to your inbox.

Email address